KR20180054856A - 이중 dyrk1/clk1 억제제로서의 신규한 피롤로[2,3-d]피리미딘 유도체 - Google Patents

이중 dyrk1/clk1 억제제로서의 신규한 피롤로[2,3-d]피리미딘 유도체 Download PDF

Info

Publication number
KR20180054856A
KR20180054856A KR1020187012166A KR20187012166A KR20180054856A KR 20180054856 A KR20180054856 A KR 20180054856A KR 1020187012166 A KR1020187012166 A KR 1020187012166A KR 20187012166 A KR20187012166 A KR 20187012166A KR 20180054856 A KR20180054856 A KR 20180054856A
Authority
KR
South Korea
Prior art keywords
methyl
group
formula
compound
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187012166A
Other languages
English (en)
Korean (ko)
Inventor
안드레아 피우마나
니콜라스 폴로페
스튜어트 레이
데이비드 웜슬리
안드라스 코치
미첼 프랭크 버브리지
프란시스코 험베르토 크루자레귀
Original Assignee
르 라보레또레 쎄르비에르
베르날리스 (알 앤드 디) 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 르 라보레또레 쎄르비에르, 베르날리스 (알 앤드 디) 리미티드 filed Critical 르 라보레또레 쎄르비에르
Publication of KR20180054856A publication Critical patent/KR20180054856A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187012166A 2015-09-30 2016-09-30 이중 dyrk1/clk1 억제제로서의 신규한 피롤로[2,3-d]피리미딘 유도체 Withdrawn KR20180054856A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR15/59259 2015-09-30
FR1559259A FR3041640B1 (fr) 2015-09-30 2015-09-30 NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
PCT/EP2016/073403 WO2017055533A1 (en) 2015-09-30 2016-09-30 New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors

Publications (1)

Publication Number Publication Date
KR20180054856A true KR20180054856A (ko) 2018-05-24

Family

ID=54979756

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187012166A Withdrawn KR20180054856A (ko) 2015-09-30 2016-09-30 이중 dyrk1/clk1 억제제로서의 신규한 피롤로[2,3-d]피리미딘 유도체

Country Status (26)

Country Link
US (1) US20180273538A1 (cg-RX-API-DMAC10.html)
EP (1) EP3356364A1 (cg-RX-API-DMAC10.html)
JP (1) JP2018533552A (cg-RX-API-DMAC10.html)
KR (1) KR20180054856A (cg-RX-API-DMAC10.html)
CN (1) CN108137582A (cg-RX-API-DMAC10.html)
AU (1) AU2016333508A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018005851A2 (cg-RX-API-DMAC10.html)
CA (1) CA2999937A1 (cg-RX-API-DMAC10.html)
CL (1) CL2018000786A1 (cg-RX-API-DMAC10.html)
CO (1) CO2018003466A2 (cg-RX-API-DMAC10.html)
CR (1) CR20180176A (cg-RX-API-DMAC10.html)
CU (1) CU20180027A7 (cg-RX-API-DMAC10.html)
DO (1) DOP2018000082A (cg-RX-API-DMAC10.html)
EA (1) EA201890820A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP18023286A (cg-RX-API-DMAC10.html)
FR (1) FR3041640B1 (cg-RX-API-DMAC10.html)
HK (1) HK1255467A1 (cg-RX-API-DMAC10.html)
IL (1) IL258231A (cg-RX-API-DMAC10.html)
MA (1) MA43021A (cg-RX-API-DMAC10.html)
MX (1) MX2018003861A (cg-RX-API-DMAC10.html)
NI (1) NI201800042A (cg-RX-API-DMAC10.html)
PE (1) PE20190337A1 (cg-RX-API-DMAC10.html)
PH (1) PH12018500605A1 (cg-RX-API-DMAC10.html)
SV (1) SV2018005656A (cg-RX-API-DMAC10.html)
TN (1) TN2018000087A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017055533A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
EP3856186A4 (en) * 2018-09-28 2022-07-06 Arizona Board of Regents on behalf of the University of Arizona SMALL MOLECULAR DYRK1/CLK INHIBITORS AND USES THEREOF
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
AR120799A1 (es) * 2019-12-20 2022-03-16 Hoffmann La Roche 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr
CN116783198B (zh) * 2020-12-02 2025-10-21 广东弘烨医药科技有限公司 螺环jak抑制剂、含其的药物组合物及其应用
WO2022245776A1 (en) * 2021-05-20 2022-11-24 Saint John's Cancer Institute Anti-cdk inhibitors for cancer treatment
WO2023064349A1 (en) * 2021-10-12 2023-04-20 Biosplice Therapeutics, Inc. 1h-pyrrolo[2,3-b]pyridines as dyrk1a inhibitors
TW202330533A (zh) * 2021-10-12 2023-08-01 美商生物銜接醫療公司 7h-吡咯并[2,3-d]嘧啶及其製備及用途
MX2024004552A (es) 2021-10-12 2024-06-04 Biosplice Therapeutics Inc Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas.
WO2023110843A1 (en) * 2021-12-15 2023-06-22 Almirall, S.A. Heterobicyclic derivatives as itk inhibitors
CN116621843B (zh) * 2022-06-13 2024-05-24 四川大学华西医院 一种dna甲基转移酶1抑制剂及其制备方法和用途
CN115785134B (zh) * 2022-10-28 2023-08-29 浙大城市学院 一种含氮杂环的硼酸化合物及制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008041053A2 (en) 2005-05-20 2008-04-10 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
JP2009511527A (ja) 2005-10-13 2009-03-19 グラクソ グループ リミテッド Syk阻害物質としてのピロロピリミジン誘導体
CA2645343A1 (en) 2006-03-11 2007-09-20 Vernalis (R&D) Limited Pyrrolopyrimidine derivatives used as hsp90 inhibitors
FR2912744B1 (fr) * 2007-02-16 2012-09-07 Centre Nat Rech Scient Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
EA025186B1 (ru) * 2012-06-29 2016-11-30 Пфайзер Инк. НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
EP3083618B1 (en) * 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors

Also Published As

Publication number Publication date
FR3041640A1 (cg-RX-API-DMAC10.html) 2017-03-31
CN108137582A (zh) 2018-06-08
CR20180176A (es) 2018-05-31
AU2016333508A1 (en) 2018-04-12
MA43021A (fr) 2018-08-08
WO2017055533A1 (en) 2017-04-06
EP3356364A1 (en) 2018-08-08
DOP2018000082A (es) 2018-10-15
CO2018003466A2 (es) 2018-07-10
NI201800042A (es) 2018-06-21
PH12018500605A1 (en) 2018-09-24
JP2018533552A (ja) 2018-11-15
ECSP18023286A (es) 2018-04-30
PE20190337A1 (es) 2019-03-07
HK1255467A1 (zh) 2019-08-16
US20180273538A1 (en) 2018-09-27
MX2018003861A (es) 2018-08-16
TN2018000087A1 (en) 2019-07-08
BR112018005851A2 (pt) 2018-10-09
IL258231A (en) 2018-05-31
FR3041640B1 (fr) 2019-05-17
EA201890820A1 (ru) 2018-10-31
CU20180027A7 (es) 2018-07-05
SV2018005656A (es) 2018-08-10
CL2018000786A1 (es) 2018-09-28
CA2999937A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
AU2016333508A1 (en) New pyrrolo[2,3-d]pyrimidine derivatives as dual DYRK1/CLK1 inhibitors
EP3152210B1 (en) Tank-binding kinase inhibitor compounds
RU2673079C2 (ru) Ингибиторные соединения
EP3205650B1 (en) Egfr inhibitor, and preparation and application thereof
RU2615130C2 (ru) Гетероциклические соединения, используемые в качестве ингибиторов pdk1
EP2970312B1 (en) Bet bromodomain inhibitors and therapeutic methods using the same
CN105461695B (zh) 嘧啶或三嗪衍生物及其制备方法和用途
US20120309739A1 (en) Akt / pkb inhibitors
CN106928219B (zh) 含氮稠杂环化合物、制备方法、中间体、组合物和应用
AU2016282836A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
US10239873B2 (en) 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same
RS64131B1 (sr) Novi derivati hidroksikiselina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže
KR20150143672A (ko) Ras/raf/mek/erk 및 pi3k/akt/pten/mtor 경로의 이중 억제제로서의 퀴나졸린 및 아자퀴나졸린
EP3313850A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
KR20230035236A (ko) 아데노신 a2a 수용체의 길항제
AU2018337138B2 (en) 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
CN109810098B (zh) 含有酞嗪-1(2h)-酮结构的parp-1和pi3k双靶点抑制剂
JP7233130B2 (ja) Irak4阻害剤としての新規な三環式化合物
AU2014316247A1 (en) Novel 2,6-diaminopyrimidine derivative
CN113574057A (zh) 杂芳基衍生物及包含其作为活性成分的药物组合物
OA18644A (en) New pyrrolo[2,3-d]pyrimidine derivatives as dual DYRK1/CLK1 inhibitors.
CA2716202A1 (en) Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as pkc-theta inhibitors
CN112209934A (zh) 含有氮杂螺庚烷的btk抑制剂
EA049140B1 (ru) Замещенные конденсированные гетероароматические бициклические соединения в качестве ингибиторов киназ и их применение
HK1236197A1 (en) Tank-binding kinase inhibitor compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180427

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid